Answers are grounded in this paper and cite their sources.
This supplement of Transplantation not only celebrates the decade since the introduction of mycophenolate mofetil (MMF) into clinical practice but also the successful completion of the complicated development process that led to its approval. The series of remarkable clinical trials (1–3) that culminated in the registration of MMF throughout the world in the mid-1990s proved to be of inestimable importance to the transplant community, forever altering the face of clinical research in solid organ transplantation. The reports in this supplement have allowed us to nostalgically reflect on the heady days that accompanied the unblinding of those trials as well as to review what we have since learned and still need to understand about this multifaceted agent. The theoretical underpinnings for the immunosuppressive action of MMF have been elegantly summarized in this issue by Allison and Eugui (4). In retrospect, the progress from animal models to early phase clinical trials through registration trials and eventual widespread clinical use seems inexorable. It did not appear so at the onset. The clinical development of new immunosuppressive agents has taken place largely in the arena of renal transplantation, reflecting the large volume of procedures performed. At the time of the MMF registration trials, renal allograft survival in most centers was typically greater than 85% at 1 year posttransplant, following the introduction of cyclosporine a decade earlier. It was recognized early on that a study endpoint of reduced graft loss was impractical. Thus, for the first time in transplantation the concept of a surrogate marker was accepted, with reduction in the incidence of acute rejection the being the agreed-upon endpoint. As noted by Ciancio et al. (5), the registration trials for MMF were unprecedented in many respects. First and foremost, they were a massive undertaking involving 1500 patients at 55 transplant centers on three continents. Their sheer size illustrates what an imposing challenge it is to introduce a new immunosuppressive drug in transplantation. The registration trials were the initial prospective, double-blind trials performed in transplantation, and in many respects, their design became a blueprint for subsequent trials of other immunosuppressive agents now available or in development. In addition to convincingly demonstrating that MMF was a potent and relatively nontoxic immunosuppressant, these trials permitted other observations that have since become accepted concepts. The great majority of acute rejection episodes in compliant patients took place within the first three months posttransplant; this consistent chronology provided a relatively rapid and reliable clinical model by which new immunosuppressive agents could be tested. Also, the United States registration trial demonstrated that African-American patients required higher levels of immunosuppression to achieve reductions in acute rejection episodes similar to those reported in non-African Americans (1). These findings were subsequently mirrored in the pivotal trials of tacrolimus and the use of higher levels of immunosuppression in African Americans has become accepted clinical practice (6). The particular challenges encountered with the introduction of MMF into pediatric kidney transplantation are discussed in this supplement by Ettenger and Sarwal (7). Thanks to a series of studies specifically designed to address pediatric dosing and side effects, the use of MMF in pediatric transplantation has closely paralleled that of adult transplantation, and close to 60% of pediatric recipients are now receiving the drug (8). The initial trials of MMF in renal transplantation had an unanticipated impact on drug development in the field of transplantation. The clear-cut benefits of MMF in reducing the risk of acute rejection rapidly led to its clinical acceptance. By the late 1990s, close to 80% of patients were receiving MMF upon hospital discharge in the United States, a figure that has remained consistent ever since (9). When MMF was combined with either cyclosporine or tacrolimus and an anti-CD25 antibody, acute rejection incidences of 10% or lower were routinely achieved in many programs. A new standard was thereby set against which new drugs or protocols needed to be compared. Reduction of acute rejection episodes became a more difficult target, engendering the current need for definition of new or composite endpoints (10). The difficulty in proving the relative benefits of new immunosuppressants in transplantation may account for the fact that the clinical use of new agents such as alemtuzumab and leflunamide has taken place through the “back door” of their approval for other indications. Not all of the anticipated benefits of MMF were documented in the initial registration trials. Neither MMF nor any other immunosuppressive drug since cyclosporine has been able to provide statistically convincing evidence of reduction in graft loss. This is despite the demonstrated positive impact of MMF on the risk of acute rejection. However, the retrospective analysis by Srinivas et al. (11) provides supportive evidence that MMF does indeed have a beneficial impact on graft survival. As confidence in the immunosuppressive efficacy of MMF grew, it seemed rational to exploit MMF’s relatively benign toxicity profile (particularly the absence of nephrotoxicity) to minimize the negative effects of other immunosuppressants. Land and Vincenti (12) review various MMF-based toxicity-sparing protocols that minimize or altogether avoid the use of corticosteroids or calcineurin inhibitors, a growing trend in clinical practice. By 2002, 9% of kidney transplant recipients in the United States did not receive postdischarge corticosteroid maintenance (9). For patients already suffering from deteriorating renal function as a result of chronic allograft nephropathy, Weir et al. (13) showed that the rate of deterioration could be slowed or even reversed by combining MMF with discontinuation or drastic dose reduction of calcineurin inhibitors. These observations have since been confirmed in a randomized, prospective trial by Dudley et al. (14). For the great majority of patients, the use of MMF with relatively low doses of a calcineurin inhibitor would seem to be a safe and rational protocol for long-term use and, indeed, this practice is now commonplace. It did not take long for the relative benefits of MMF that were demonstrated in renal transplantation to be reproduced in cardiac transplantation and for MMF to be introduced into the immunosuppressive regimens of patients receiving other types of allografts. Kobashigawa and Meiser (15) review the acceptance of MMF in cardiac transplantation, which is based on results of the first large multicenter trial ever performed in this population, involving 650 patients in 28 centers around the world. In addition to demonstrating a reduction of mortality and both the incidence and severity of rejection with MMF, there was also a benefit in preserving coronary artery luminal area at 1-year posttransplant. The implications of this finding may be important not just for cardiac transplant recipients, but for recipients of other allografts as well, since vasculopathy may represent the final common pathway leading to eventual graft loss. MMF is now used in approximately 80% of heart and pancreas transplant recipients, and a somewhat lesser percentage of liver and lung recipients (5). After a decade of clinical use, important questions about MMF remain to be answered. The fixed-dosing regimens used in the original clinical trials are now routinely used and have been regarded as an advantage for MMF because it made administration very simple. Yet one might expect that more sophisticated and individualized dosing might make the drug even more effective and safer. Van Gelder and Shaw (16) review the topic of therapeutic drug level monitoring and describe clinical trials that are in progress to help resolve the question of whether monitoring should be conducted in all patients receiving MMF. Since single sample monitoring of MPA is unlikely to be effective, it is also unlikely that clinical therapeutic drug monitoring in transplantation will become widespread at this stage in the drug’s development. Fear that the immunosuppressive effectiveness of MMF would be accompanied by an increased incidence of malignancy over and above that associated with other immunosuppressants has not been realized and, as Buell et al. (17) note, there are some preliminary data to suggest an anti-tumor effect of the drug. It has been gratifying to see the introduction of MMF as a therapeutic immunosuppressant in a variety of autoimmune diseases (18). Clinical trials in patients with autoimmune disorders are difficult because their disease course is unpredictable, making it hard to define therapeutic benefits. Nonetheless, enough supportive evidence has accumulated to permit acceptance of MMF as a therapeutic option for systemic lupus erythematosus, and it has been used with apparent success to treat a variety of glomerulonephritides, rheumatologic disorders, and inflammatory bowel diseases. In addition, the emerging evidence of a synergism between MMF and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers raises intriguing possibilities of still broader indications for the use this drug (4). Additional studies in these areas are clearly of great interest. This past decade has seen MMF mature from being the “new kid on the block” in organ transplantation to being an established member of the immunosuppressive armamentarium. Familiarity with MMF has further increased the confidence with which it is used. Because of its effectiveness and favorable side effect profile, it is likely to remain a cornerstone of immunosuppression for both transplantation and autoimmune disease in the next decade as well. Those involved in the discovery, development, and clinical investigations of this preeminent agent are to be congratulated on their invaluable contribution.
No takes yet. Share an insight, caveat, or question.
Gabriel M. Danovitch (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: